Search research articles
Contact Us
Filters
Showing results (31-40 of 341) with videos related to
Page
of 35
Sort By:
Cancer
|
October 7, 2018
Toward the potential cure of leukemias in the next decade
Hagop M Kantarjian, Michael J Keating, Emil J Freireich
Current Hematologic Malignancy Reports
|
December 15, 2010
What is the best frontline therapy for patients with CLL and 17p deletion?
Xavier C Badoux, Michael J Keating, William G Wierda
Blood
|
June 24, 2005
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death
Rong Chen, Michael J Keating, Varsha Gandhi, et al.
Nature Reviews. Drug Discovery
|
February 18, 2006
Nelarabine
Varsha Gandhi, Michael J Keating, Guy Bate, et al.
Anti-Cancer Drugs
|
April 25, 2003
Rituximab in B-cell disorders other than non-Hodgkin's lymphoma
Andre Bosly, Michael J Keating, Roberto Stasi, et al.
The New England Journal of Medicine
|
April 21, 2016
Ibrutinib for Chronic Lymphocytic Leukemia
Jeff P Sharman, Anthony R Mato, Michael J Keating
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 13, 2005
Novel immune-based treatment strategies for chronic lymphocytic leukemia
William G Wierda, Thomas J Kipps, Michael J Keating
Current Hematologic Malignancy Reports
|
April 29, 2010
Richter's transformation in chronic lymphocytic leukemia
Apostolia-Maria Tsimberidou, Michael J Keating, William G Wierda
Clinical Lymphoma & Myeloma
|
October 10, 2006
Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab
Susan M O'Brien, Michael J Keating, Edward S Mocarski
Future Oncology (London, England)
|
February 17, 2015
Shifting paradigms in the treatment of chronic lymphocytic leukemia
Philip A Thompson, Elizabeth J Shpall, Michael J Keating
Page
of 35
Search research articles
Search
Showing results (31-40 of 341) with videos related to
Sort By:
Page
of 35
Cancer
|
October 7, 2018
Toward the potential cure of leukemias in the next decade
Hagop M Kantarjian, Michael J Keating, Emil J Freireich
Current Hematologic Malignancy Reports
|
December 15, 2010
What is the best frontline therapy for patients with CLL and 17p deletion?
Xavier C Badoux, Michael J Keating, William G Wierda
Blood
|
June 24, 2005
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death
Rong Chen, Michael J Keating, Varsha Gandhi, et al.
Nature Reviews. Drug Discovery
|
February 18, 2006
Nelarabine
Varsha Gandhi, Michael J Keating, Guy Bate, et al.
Anti-Cancer Drugs
|
April 25, 2003
Rituximab in B-cell disorders other than non-Hodgkin's lymphoma
Andre Bosly, Michael J Keating, Roberto Stasi, et al.
The New England Journal of Medicine
|
April 21, 2016
Ibrutinib for Chronic Lymphocytic Leukemia
Jeff P Sharman, Anthony R Mato, Michael J Keating
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 13, 2005
Novel immune-based treatment strategies for chronic lymphocytic leukemia
William G Wierda, Thomas J Kipps, Michael J Keating
Current Hematologic Malignancy Reports
|
April 29, 2010
Richter's transformation in chronic lymphocytic leukemia
Apostolia-Maria Tsimberidou, Michael J Keating, William G Wierda
Clinical Lymphoma & Myeloma
|
October 10, 2006
Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab
Susan M O'Brien, Michael J Keating, Edward S Mocarski
Future Oncology (London, England)
|
February 17, 2015
Shifting paradigms in the treatment of chronic lymphocytic leukemia
Philip A Thompson, Elizabeth J Shpall, Michael J Keating
Page
of 35